M&A activity reached a record high the past couple of years. Buyers commonly pursue deals in order to strengthen product development and R&D capabilities. However, in many cases, the value of the acquisition will likely fall short for a number of reasons that may originate during the early stages of the deal inception all the way up to the integration phase.
In this webinar we discuss common reasons why realized value may be lower than expected and ways to mitigate it. If you anticipate working with a potential buyer in the near future, you'll want to hear Mr. Eliadis' recommendations for avoiding these common pitfalls.

request the recording
of the webinar




ShareVault’s secure document sharing solution gives pharmaceutical and biotechnology  organizations the confidence to simply and securely share sensitive documents with third parties during due diligence, product development, technology transfers, fundraising, partnering, collaborative research and other activities that require the highest level of document security.

Compared to consumer-grade solutions, ShareVault virtual data rooms offer many features that give you control and document intelligence with the highest level of document-protection and monitoring available. Learn more.